樂觀
$100.88
情境價格
$57.400
+2.635 (+4.59%)收盤時
The Cooper Companies, Inc. is a medical device company. The Company's segments include CooperVision and CooperSurgical. The CooperVision segment is engaged in developing, manufacturing and marketing a broad range of products for contact lens wearers, featuring advanced materials and optics. Its daily disposable silicone hydrogel contact lens products include MyDay daily disposable, MyDay daily disposable toric, MyDay daily disposable multifocal, and MyDay Energys. The CooperSurgical segment provides a portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. Its brands include ALLY II UPS, Advincula Delineator, Apple-Hunt Secondary Cannula, Bakri Postpartum Balloon, California Cryobank, Carter-Thomason, Cell Care, Cells for Life, Coda, Cord Blood Registry, Core Cryolab, Donor Egg Bank USA, ER-Complete, Embryo Options, and Endosee.
Currently, Cooper Companies Inc is trading at $54.37, which is below the average analyst price target of $73. This suggests potential upside. However, the RSI is at 27.192, indicating the stock is oversold, which could lead to a price rebound. The company has shown a significant net income increase to $432.8 million in Q3 2026, but it also reported a net loss of $77.9 million in Q2 2026, indicating volatility. The main risk is the forecasted revenue growth of only 0% to 2% for Q4 2026, which could limit short-term price appreciation.
Barclays
$60
2026-10-06
Barclays
2026-10-06
目標價
$60
Mizuho
$75
2026-09-11
Mizuho
2026-09-11
目標價
$75
JPMorgan
$58
2026-09-10
JPMorgan
2026-09-10
目標價
$58
Needham
$73
2026-09-10
Needham
2026-09-10
目標價
$73
Citi
$60
2026-09-10
Citi
2026-09-10
目標價
$60
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

Rosen Law Firm Investigates Securities Claims Against The Cooper Companies

Kurzius Increases Stake in Cooper Companies

Director Paul A. Keel Acquires $250,000 in Cooper Companies Shares

Cooper Companies Director Increases Stock Holdings

Rosen Law Firm Investigates Securities Claims Against Cooper Companies
The Cooper Companies, Inc. is a medical device company. The Company's segments include CooperVision and CooperSurgical. The CooperVision segment is engaged in developing, manufacturing and marketing a broad range of products for contact lens wearers, featuring advanced materials and optics. Its daily disposable silicone hydrogel contact lens products include MyDay daily disposable, MyDay daily disposable toric, MyDay daily disposable multifocal, and MyDay Energys. The CooperSurgical segment provides a portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. Its brands include ALLY II UPS, Advincula Delineator, Apple-Hunt Secondary Cannula, Bakri Postpartum Balloon, California Cryobank, Carter-Thomason, Cell Care, Cells for Life, Coda, Cord Blood Registry, Core Cryolab, Donor Egg Bank USA, ER-Complete, Embryo Options, and Endosee. It operates in the Healthcare sector (OPHTHALMIC GOODS industry).
Currently, Cooper Companies Inc is trading at $54.37, which is below the average analyst price target of $73. This suggests potential upside. However, the RSI is at 27.192, indicating the stock is oversold, which could lead to a price rebound. The company has shown a significant net income increase to $432.8 million in Q3 2026, but it also reported a net loss of $77.9 million in Q2 2026, indicating volatility. The main risk is the forecasted revenue growth of only 0% to 2% for Q4 2026, which could limit short-term price appreciation.
15 analysts cover COO: 10 rate it Buy, 5 Hold and 0 Sell. The average price target is 90.33.
暫無貼文
註冊或登入後參與討論本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。